Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy - Trial NCT06151249
Access comprehensive clinical trial information for NCT06151249 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chung Shan Medical University and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chung Shan Medical University
Timeline & Enrollment
Phase 2
Dec 01, 2023
Nov 30, 2025
Primary Outcome
Changes in fatigue scores
Summary
A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile
 and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients
 receiving chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06151249
Non-Device Trial